Novain (Oxybuprocaine Hydrochloride)

Oxybuprocaine Hydrochloride, the active ingredient in Novain, is a local anesthetic (ester type) presented as a sterile ophthalmic solution for ocular topical use. It provides rapid surface anesthesia for diagnostic eye examinations and minor ocular procedures.

GNH USA supplies Novain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across EU and global markets, and follows stringent Good Distribution Practice standards and provides reliable logistics for timely delivery to healthcare providers.

Novain, containing Oxybuprocaine Hydrochloride, is used for topical ocular anesthesia, providing rapid numbness of the corneal and conjunctival surfaces. - Diagnostic eye examinations: enables painless corneal sensitivity testing, fluorescein staining and slit‑lamp evaluation. - Minor ocular procedures: provides analgesia for foreign body removal, laser photocoagulation and superficial surgeries. - Intraocular pressure measurement: reduces discomfort during tonometry and other pressure‑assessment techniques. - Pre‑operative ocular assessment: facilitates patient comfort before cataract or refractive surgery planning. - Contact lens fitting: provides temporary anesthesia to allow safe lens insertion and removal during fitting sessions.

Topical ocular application of Oxybuprocaine Hydrochloride may be associated with a range of local adverse reactions, most of which are mild and transient.

Common Side Effects: - Transient stinging or burning sensation upon instillation. - Mild ocular redness or hyperemia. - Temporary blurred vision lasting a few minutes. - Tearing or lacrimation. - Mild conjunctival irritation.

Serious or Rare Side Effects: - Allergic contact dermatitis presenting as itching, swelling, or rash. - Corneal epithelial toxicity leading to ulceration or delayed healing. - Severe intraocular inflammation such as uveitis. - Systemic toxicity such as central nervous system effects (rare).

When using Novain, several precautionary measures should be observed to minimize risk and ensure optimal efficacy. - Allergy assessment: avoid use in patients with known hypersensitivity to ester‑type ocular anesthetics. - Contact lens removal: ensure lenses are removed prior to instillation to prevent drug entrapment. - Duration of exposure: limit application to a single diagnostic procedure unless otherwise directed by a clinician. - Concomitant ocular medications: evaluate for potential additive irritation when used with other eye drops. - Pediatric use: exercise caution and follow specialist guidance when administering to children. - Store at room temperature: keep in the original container, protect from light and moisture.

Oxybuprocaine Hydrochloride can interact with other ophthalmic agents; awareness of these interactions helps maintain safety.

Major Interactions (Avoid): - Concurrent use of other topical anesthetics: may cause cumulative corneal toxicity. - Cholinergic agents (e.g., pilocarpine): can increase ocular irritation and discomfort.

Moderate Interactions (Monitor Closely): - Antibiotic eye drops (e.g., fluoroquinolones): monitor for delayed corneal healing. - Anti‑inflammatory eye drops (e.g., corticosteroids): assess for additive effects on ocular surface. - Systemic sodium channel blockers (e.g., antiarrhythmics): observe for rare enhanced systemic absorption.